Amedeo Smart

Free Medical Literature Service


 

Amedeo

Influenza

  Free Subscription

Articles published in
PLoS Biol
    January 2025
  1. MEARS HV, Young GR, Sanderson T, Harvey R, et al
    Emergence of SARS-CoV-2 subgenomic RNAs that enhance viral fitness and immune evasion.
    PLoS Biol. 2025;23:e3002982.
    >> Share

    December 2024
  2. KUCHARSKI AJ
    Controlling minor outbreaks is necessary to prepare for major pandemics.
    PLoS Biol. 2024;22:e3002945.
    >> Share

    November 2024
  3. DADONAITE B, Ahn JJ, Ort JT, Yu J, et al
    Deep mutational scanning of H5 hemagglutinin to inform influenza virus surveillance.
    PLoS Biol. 2024;22:e3002916.
    >> Share

  4. HAY JA, Zhu H, Jiang CQ, Kwok KO, et al
    Reconstructed influenza A/H3N2 infection histories reveal variation in incidence and antibody dynamics over the life course.
    PLoS Biol. 2024;22:e3002864.
    >> Share

    September 2024
  5. LE PEN J, Paniccia G, Kinast V, Moncada-Velez M, et al
    A genome-wide arrayed CRISPR screen identifies PLSCR1 as an intrinsic barrier to SARS-CoV-2 entry that recent virus variants have evolved to resist.
    PLoS Biol. 2024;22:e3002767.
    >> Share

    March 2024
  6. BEKDASH R, Yoshida K, Nair MS, Qiu L, et al
    Developing inhibitory peptides against SARS-CoV-2 envelope protein.
    PLoS Biol. 2024;22:e3002522.
    >> Share

    January 2024
  7. RUSSELL TW, Townsley H, Abbott S, Hellewell J, et al
    Combined analyses of within-host SARS-CoV-2 viral kinetics and information on past exposures to the virus in a human cohort identifies intrinsic differences of Omicron and Delta variants.
    PLoS Biol. 2024;22:e3002463.
    >> Share

    December 2023
  8. SIMMONS HC, Watanabe A, Oguin Iii TH, Van Itallie ES, et al
    A new class of antibodies that overcomes a steric barrier to cross-group neutralization of influenza viruses.
    PLoS Biol. 2023;21:e3002415.
    >> Share

    November 2023
  9. VALE-COSTA S, Etibor TA, Bras D, Sousa AL, et al
    ATG9A regulates the dissociation of recycling endosomes from microtubules to form liquid influenza A virus inclusions.
    PLoS Biol. 2023;21:e3002290.
    >> Share

  10. ZHU Z, Fan H, Fodor E
    Defining the minimal components of the influenza A virus replication machinery via an in vitro reconstitution system.
    PLoS Biol. 2023;21:e3002370.
    >> Share

  11. KALIMUDDIN S, Ooi EE
    Minding the "T"s beyond the "B"s: Shaping vaccines for future pandemics.
    PLoS Biol. 2023;21:e3002351.
    >> Share

  12. LYTRAS S, Wickenhagen A, Sugrue E, Stewart DG, et al
    Resurrection of 2'-5'-oligoadenylate synthetase 1 (OAS1) from the ancestor of modern horseshoe bats blocks SARS-CoV-2 replication.
    PLoS Biol. 2023;21:e3002398.
    >> Share

    August 2023
  13. LADNER JT, Sahl JW
    Towards a post-pandemic future for global pathogen genome sequencing.
    PLoS Biol. 2023;21:e3002225.
    >> Share

  14. LOBINSKA G, Pilpel Y, Nowak MA
    Evolutionary safety of lethal mutagenesis driven by antiviral treatment.
    PLoS Biol. 2023;21:e3002214.
    >> Share

  15. KRAFT TS, Seabright E, Alami S, Jenness SM, et al
    Metapopulation dynamics of SARS-CoV-2 transmission in a small-scale Amazonian society.
    PLoS Biol. 2023;21:e3002108.
    >> Share

    July 2023
  16. OLAJIDE OM, Osman MK, Robert J, Kessler S, et al
    Evolutionarily conserved amino acids in MHC-II mediate bat influenza A virus entry into human cells.
    PLoS Biol. 2023;21:e3002182.
    >> Share

    June 2023
  17. STRINE MS, Cai WL, Wei J, Alfajaro MM, et al
    DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner.
    PLoS Biol. 2023;21:e3002097.
    >> Share

  18. CHEN NFG, Chaguza C, Gagne L, Doucette M, et al
    Development of an amplicon-based sequencing approach in response to the global emergence of mpox.
    PLoS Biol. 2023;21:e3002151.
    >> Share

  19. TSU BV, Agarwal R, Gokhale NS, Kulsuptrakul J, et al
    Host-specific sensing of coronaviruses and picornaviruses by the CARD8 inflammasome.
    PLoS Biol. 2023;21:e3002144.
    >> Share

    May 2023
  20. EALES O, Haw D, Wang H, Atchison C, et al
    Dynamics of SARS-CoV-2 infection hospitalisation and infection fatality ratios over 23 months in England.
    PLoS Biol. 2023;21:e3002118.
    >> Share

    February 2023
  21. SIMS A, Tornaletti LB, Jasim S, Pirillo C, et al
    Superinfection exclusion creates spatially distinct influenza virus populations.
    PLoS Biol. 2023;21:e3001941.
    >> Share

  22. SHILTS J, Crozier TWM, Teixeira-Silva A, Gabaev I, et al
    LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike protein.
    PLoS Biol. 2023;21:e3001959.
    >> Share

  23. LOO L, Waller MA, Moreno CL, Cole AJ, et al
    Fibroblast-expressed LRRC15 is a receptor for SARS-CoV-2 spike and controls antiviral and antifibrotic transcriptional programs.
    PLoS Biol. 2023;21:e3001967.
    >> Share

  24. PIELKE R JR
    Improve how science advice is provided to governments by learning from "experts in expert advice".
    PLoS Biol. 2023;21:e3002004.
    >> Share

  25. TANG AT, Buchholz DW, Szigety KM, Imbiakha B, et al
    Cell-autonomous requirement for ACE2 across organs in lethal mouse SARS-CoV-2 infection.
    PLoS Biol. 2023;21:e3001989.
    >> Share

    December 2022
  26. BAKER SF, Meistermann H, Tzouros M, Baker A, et al
    Alternative splicing liberates a cryptic cytoplasmic isoform of mitochondrial MECR that antagonizes influenza virus.
    PLoS Biol. 2022;20:e3001934.
    >> Share

    November 2022
  27. MESCI P, de Souza JS, Martin-Sancho L, Macia A, et al
    SARS-CoV-2 infects human brain organoids causing cell death and loss of synapses that can be rescued by treatment with Sofosbuvir.
    PLoS Biol. 2022;20:e3001845.
    >> Share

  28. GARCIA G JR, Jeyachandran AV, Wang Y, Irudayam JI, et al
    Hippo signaling pathway activation during SARS-CoV-2 infection contributes to host antiviral response.
    PLoS Biol. 2022;20:e3001851.
    >> Share

  29. NIEMEYER D, Stenzel S, Veith T, Schroeder S, et al
    SARS-CoV-2 variant Alpha has a spike-dependent replication advantage over the ancestral B.1 strain in human cells with low ACE2 expression.
    PLoS Biol. 2022;20:e3001871.
    >> Share

    October 2022
  30. SONG J, Chow RD, Pena-Hernandez MA, Zhang L, et al
    LRRC15 inhibits SARS-CoV-2 cellular entry in trans.
    PLoS Biol. 2022;20:e3001805.
    >> Share

    September 2022
  31. DAY T, Kennedy DA, Read AF, Gandon S, et al
    Pathogen evolution during vaccination campaigns.
    PLoS Biol. 2022;20:e3001804.
    >> Share

  32. CHING KL, de Vries M, Gago J, Dancel-Manning K, et al
    ACE2-containing defensosomes serve as decoys to inhibit SARS-CoV-2 infection.
    PLoS Biol. 2022;20:e3001754.
    >> Share

  33. FERNBACH S, Hale BG
    SARS-CoV-2 takes the bait: Exosomes as endogenous decoys.
    PLoS Biol. 2022;20:e3001787.
    >> Share

    August 2022
  34. LIU H, Riggi M, Rogers J, Meyer M, et al
    A new tool for annotating scientific animations and supporting scientific dialogue.
    PLoS Biol. 2022;20:e3001731.
    >> Share

  35. ZHU Y, Chew KY, Wu M, Karawita AC, et al
    Ancestral SARS-CoV-2, but not Omicron, replicates less efficiently in primary pediatric nasal epithelial cells.
    PLoS Biol. 2022;20:e3001728.
    >> Share

    July 2022
  36. BUSNADIEGO I, Abela IA, Frey PM, Hofmaenner DA, et al
    Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease.
    PLoS Biol. 2022;20:e3001709.
    >> Share

  37. ROELLE SM, Shukla N, Pham AT, Bruchez AM, et al
    Expanded ACE2 dependencies of diverse SARS-like coronavirus receptor binding domains.
    PLoS Biol. 2022;20:e3001738.
    >> Share

    June 2022
  38. GRIFFIN DE
    Why does viral RNA sometimes persist after recovery from acute infections?
    PLoS Biol. 2022;20:e3001687.
    >> Share

  39. TAUBE JC, Miller PB, Drake JM
    An open-access database of infectious disease transmission trees to explore superspreader epidemiology.
    PLoS Biol. 2022;20:e3001685.
    >> Share

    May 2022
  40. ZHU DY, Gorman MJ, Yuan D, Yu J, et al
    Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates.
    PLoS Biol. 2022;20:e3001609.
    >> Share

  41. LU-CULLIGAN A, Tabachnikova A, Perez-Then E, Tokuyama M, et al
    No evidence of fetal defects or anti-syncytin-1 antibody induction following COVID-19 mRNA vaccination.
    PLoS Biol. 2022;20:e3001506.
    >> Share

  42. SYENINA A, Gan ES, Toh JZN, de Alwis R, et al
    Adverse effects following anti-COVID-19 vaccination with mRNA-based BNT162b2 are alleviated by altering the route of administration and correlate with baseline enrichment of T and NK cell genes.
    PLoS Biol. 2022;20:e3001643.
    >> Share

  43. RICE BL, Lessler J, McKee C, Metcalf CJE, et al
    Why do some coronaviruses become pandemic threats when others do not?
    PLoS Biol. 2022;20:e3001652.
    >> Share

  44. FOLARIN RO, Maina MB, Akinbo AK, Runsewe-Abiodun TI, et al
    Bypassing shortages of personal protective equipment in low-income settings using local production and open source tools.
    PLoS Biol. 2022;20:e3001658.
    >> Share

    March 2022
  45. BESANCON L, Bik E, Heathers J, Meyerowitz-Katz G, et al
    Correction of scientific literature: Too little, too late!
    PLoS Biol. 2022;20:e3001572.
    >> Share

  46. JANG KK, Kaczmarek ME, Dallari S, Chen YH, et al
    Variable susceptibility of intestinal organoid-derived monolayers to SARS-CoV-2 infection.
    PLoS Biol. 2022;20:e3001592.
    >> Share

    February 2022
  47. FINCH E, Lowe R, Fischinger S, de St Aubin M, et al
    SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort.
    PLoS Biol. 2022;20:e3001531.
    >> Share

  48. BRIERLEY L, Nanni F, Polka JK, Dey G, et al
    Tracking changes between preprint posting and journal publication during a pandemic.
    PLoS Biol. 2022;20:e3001285.
    >> Share

    December 2021
  49. AMANAT F, Strohmeier S, Meade P, Dambrauskas N, et al
    Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus.
    PLoS Biol. 2021;19:e3001384.
    >> Share

  50. CASTIGLIONE GM, Zhou L, Xu Z, Neiman Z, et al
    Evolutionary pathways to SARS-CoV-2 resistance are opened and closed by epistasis acting on ACE2.
    PLoS Biol. 2021;19:e3001510.
    >> Share

  51. HERDER V, Dee K, Wojtus JK, Epifano I, et al
    Elevated temperature inhibits SARS-CoV-2 replication in respiratory epithelium independently of IFN-mediated innate immune defenses.
    PLoS Biol. 2021;19:e3001065.
    >> Share

    November 2021
  52. MURUATO A, Vu MN, Johnson BA, Davis-Gardner ME, et al
    Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge.
    PLoS Biol. 2021;19:e3001284.
    >> Share

    October 2021
  53. SCANLON AO JE
    Wildlife must be protected from crime and trade for the sake of public and planetary health.
    PLoS Biol. 2021;19:e3001422.
    >> Share

  54. JACK A, Ferro LS, Trnka MJ, Wehri E, et al
    SARS-CoV-2 nucleocapsid protein forms condensates with viral genomic RNA.
    PLoS Biol. 2021;19:e3001425.
    >> Share

    September 2021
  55. MOLLENTZE N, Babayan SA, Streicker DG
    Identifying and prioritizing potential human-infecting viruses from their genome sequences.
    PLoS Biol. 2021;19:e3001390.
    >> Share

    August 2021
  56. WANG SY, Takahashi T, Pine AB, Damsky WE, et al
    Challenges in interpreting cytokine data in COVID-19 affect patient care and management.
    PLoS Biol. 2021;19:e3001373.
    >> Share

    July 2021
  57. KISSLER SM, Fauver JR, Mack C, Olesen SW, et al
    Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies.
    PLoS Biol. 2021;19:e3001333.
    >> Share

  58. HOTEZ PJ
    Mounting antiscience aggression in the United States.
    PLoS Biol. 2021;19:e3001369.
    >> Share

    June 2021
  59. HEFFRON AS, McIlwain SJ, Amjadi MF, Baker DA, et al
    The landscape of antibody binding in SARS-CoV-2 infection.
    PLoS Biol. 2021;19:e3001265.
    >> Share

  60. NICHOLS JD, Bogich TL, Howerton E, Bjornstad ON, et al
    Strategic testing approaches for targeted disease monitoring can be used to inform pandemic decision-making.
    PLoS Biol. 2021;19:e3001307.
    >> Share

    May 2021
  61. VOGELS CBF, Breban MI, Ott IM, Alpert T, et al
    Multiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2.
    PLoS Biol. 2021;19:e3001236.
    >> Share

  62. FU D, Zhang G, Wang Y, Zhang Z, et al
    Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes.
    PLoS Biol. 2021;19:e3001209.
    >> Share

  63. LOWE-POWER TM, Dyson L, Polter AM
    A generation of junior faculty is at risk from the impacts of COVID-19.
    PLoS Biol. 2021;19:e3001266.
    >> Share

    April 2021
  64. MOGHADAS SM, Vilches TN, Zhang K, Nourbakhsh S, et al
    Evaluation of COVID-19 vaccination strategies with a delayed second dose.
    PLoS Biol. 2021;19:e3001211.
    >> Share

  65. FRASER N, Brierley L, Dey G, Polka JK, et al
    The evolving role of preprints in the dissemination of COVID-19 research and their impact on the science communication landscape.
    PLoS Biol. 2021;19:e3000959.
    >> Share

  66. GALLAGHER T, McCray PB Jr
    The first few days of a SARS-CoV-2 infection viewed at single-cell resolution.
    PLoS Biol. 2021;19:e3001217.
    >> Share

  67. ZHU X, Mannar D, Srivastava SS, Berezuk AM, et al
    Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies.
    PLoS Biol. 2021;19:e3001237.
    >> Share

  68. FERGUSON J, Dunn S, Best A, Mirza J, et al
    Validation testing to determine the sensitivity of lateral flow testing for asymptomatic SARS-CoV-2 detection in low prevalence settings: Testing frequency and public health messaging is key.
    PLoS Biol. 2021;19:e3001216.
    >> Share

    March 2021
  69. REVERBY SM
    Racism, disease, and vaccine refusal: People of color are dying for access to COVID-19 vaccines.
    PLoS Biol. 2021;19:e3001167.
    >> Share

  70. FULWEILER RW, Davies SW, Biddle JF, Burgin AJ, et al
    Rebuild the Academy: Supporting academic mothers during COVID-19 and beyond.
    PLoS Biol. 2021;19:e3001100.
    >> Share

  71. KIM KS, Ejima K, Iwanami S, Fujita Y, et al
    A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2.
    PLoS Biol. 2021;19:e3001128.
    >> Share

  72. MACLEAN OA, Lytras S, Weaver S, Singer JB, et al
    Natural selection in the evolution of SARS-CoV-2 in bats created a generalist virus and highly capable human pathogen.
    PLoS Biol. 2021;19:e3001115.
    >> Share

  73. POHL MO, Busnadiego I, Kufner V, Glas I, et al
    SARS-CoV-2 variants reveal features critical for replication in primary human cells.
    PLoS Biol. 2021;19:e3001006.
    >> Share

  74. RAVINDRA NG, Alfajaro MM, Gasque V, Huston NC, et al
    Single-cell longitudinal analysis of SARS-CoV-2 infection in human airway epithelium identifies target cells, alterations in gene expression, and cell state changes.
    PLoS Biol. 2021;19:e3001143.
    >> Share

    February 2021
  75. RIHN SJ, Merits A, Bakshi S, Turnbull ML, et al
    A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research.
    PLoS Biol. 2021;19:e3001091.
    >> Share

  76. COMER SP, Cullivan S, Szklanna PB, Weiss L, et al
    COVID-19 induces a hyperactive phenotype in circulating platelets.
    PLoS Biol. 2021;19:e3001109.
    >> Share

    January 2021
  77. HOTEZ PJ
    Anti-science kills: From Soviet embrace of pseudoscience to accelerated attacks on US biomedicine.
    PLoS Biol. 2021;19:e3001068.
    >> Share

    December 2020
  78. KIM JI, Park S, Bae JY, Lee S, et al
    Glycosylation generates an efficacious and immunogenic vaccine against H7N9 influenza virus.
    PLoS Biol. 2020;18:e3001024.
    >> Share

  79. REIJNS MAM, Thompson L, Acosta JC, Black HA, et al
    A sensitive and affordable multiplex RT-qPCR assay for SARS-CoV-2 detection.
    PLoS Biol. 2020;18:e3001030.
    >> Share

    November 2020
  80. KENNEDY DA, Read AF
    Monitor for COVID-19 vaccine resistance evolution during clinical trials.
    PLoS Biol. 2020;18:e3001000.
    >> Share

  81. ALTHOUSE BM, Wenger EA, Miller JC, Scarpino SV, et al
    Superspreading events in the transmission dynamics of SARS-CoV-2: Opportunities for interventions and control.
    PLoS Biol. 2020;18:e3000897.
    >> Share

  82. ZHOU Y, Hou Y, Shen J, Mehra R, et al
    A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19.
    PLoS Biol. 2020;18:e3000970.
    >> Share

  83. KADING RC, Kingston T
    Common ground: The foundation of interdisciplinary research on bat disease emergence.
    PLoS Biol. 2020;18:e3000947.
    >> Share

    October 2020
  84. KUDO E, Israelow B, Vogels CBF, Lu P, et al
    Detection of SARS-CoV-2 RNA by multiplex RT-qPCR.
    PLoS Biol. 2020;18:e3000867.
    >> Share

  85. BRUCE EA, Huang ML, Perchetti GA, Tighe S, et al
    Direct RT-qPCR detection of SARS-CoV-2 RNA from patient nasopharyngeal swabs without an RNA extraction step.
    PLoS Biol. 2020;18:e3000896.
    >> Share

  86. KUCHARSKI AJ, Funk S, Eggo RM
    The COVID-19 response illustrates that traditional academic reward structures and metrics do not reflect crucial contributions to modern science.
    PLoS Biol. 2020;18:e3000913.
    >> Share

    September 2020
  87. SELZER L, Su Z, Pintilie GD, Chiu W, et al
    Full-length three-dimensional structure of the influenza A virus M1 protein and its organization into a matrix layer.
    PLoS Biol. 2020;18:e3000827.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016